UBS upgraded Sanofi to Buy from Neutral with a price target of EUR 110, up from EUR 100, after assuming coverage of the name. The company offers above sector growth with a discounted valuation, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SNY:
- Sanofi price target raised to EUR 105 from EUR 95 at Barclays
- Sanofi upgraded to Outperform from Peer Perform at Wolfe Research
- AstraZeneca (NASDAQ:AZN) Gains on New Drug
- Exscientia expands Sanofi deal, eligible for $45M in milestones plus incentives
- Sanofi discontinuing tusamitamab ravtansine after trial did not meet endpoint